Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neratinib + trastuzumab
- Development stage
- Unknown
- Lead developer
- Puma Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Neratinib + trastuzumab is a combination therapy targeting HER2-positive breast cancer. Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that binds to cysteine residues in the ATP pocket of EGFR, HER2, and HER4, preventing autophosphorylation and downstream signaling. Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain IV of HER2. The combination prevents reactivation of HER3 and Akt phosphorylation that can occur with neratinib monotherapy, providing more complete HER2 pathway inhibition. Clinical studies have shown encouraging antitumor activity in patients with advanced HER2-positive breast cancer who have previously been treated with trastuzumab-based regimens.
- Brand names
- Nerlynx + Herceptin
- Other names
- trastuzumab-UNICANCER-biliary tract cancerSAFIR-ABC10 trastuzumab combinationSAFIR-ABC-10 trastuzumab combinationSAFIR-ABC 10 trastuzumab combination
02
Targets
ERBB4 (Erb-b2 receptor tyrosine kinase 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on neratinib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neratinib + trastuzumab.